SpeeDx announced recently that it has raised a total of $15 million from a US investment group.

Hope that we can have the opportunity to meet again in the hero city - Nanchang.

Roche recently reported flat half-year revenues for its Diagnostics division. At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business as well as to overall growth in the second quarter.

Freenome announced today that it has closed a $160 million Series B financing round, which it will use to further develop its early cancer detection blood test.

Thermo Fisher Scientific, the world leader in serving science, recently announced that it will be investing more than $50m (￡39.8m) in its global bioproduction capabilities to...

A new public-private consortium is collaborating on a project whose chief objective is an FDA-qualified composite biomarker for diagnosing nonalcoholic steatohepatitis (NASH).

Biodesix isn’t looking to just be another company with lung cancer detection tests. It wants to be the lung cancer detection company. And with its most recent acquisition, the Boulder, CO-just might achieve that goal. ..

Biological Dynamics is fighting to take its diagnostic platform to the next level. And the San Diego-based company said it recently received a grant from the Bill & Melinda Gates Foundation, to help it in its mission.

ArcherDX is bringing it up a notch through a new collaboration with Ayala Pharmaceuticals, a clinical stage precision oncology company.

At the Massachusetts institute of technology researchers have invented a sensor that can speed up the process of diagnosis of sepsis recently held in Berlin...

RNAi therapeutics firm Alnylam Pharmaceuticals and consumer genetics firm 23andMe will offer free genetic test kits to first-degree family members of 23andMe customers who have a TTR variant known to cause hereditary amyloidosis.

Illumina will bring its genomics startup incubator to the UK next year.

The Parkinson's Foundation and Fulgent Genetics announced recently that they have begun a collaboration on a new genetic testing initiative for Parkinson's disease patients.

Abbott recently said that its Diagnostics business revenues grew 2 percent year over year in the second quarter, while its total revenues were up 3 percent.

PathogenDx has entered into a strategic partnership with Nationwide Laboratory Services for fungal testing of dermatology and podiatry samples.